ResMed's New AirSense 10 Series Sleep Breathing Therapy Devices Land In China

ResMed's new AirSense 10 series sleep breathing therapy devices land in China.

Sleep apnea is a common sleep disorder, meaning no breathing or stopping breathing during sleep. It mainly manifests as snoring during nighttime sleep, loss or restriction of respiratory airflow leading to intermittent hypoxia. It causes frequent awakenings, sleeps fragmentation and other symptoms, and daytime sleepiness in some people.

In addition, recurrent nocturnal hypoxia and hypercapnia episodes due to apnea can lead to complications such as hypertension, coronary heart disease, diabetes, and cerebrovascular disease. It can involve multiple organs and systems, including respiratory, circulatory, and metabolic.

The 2016 Sleep and Occupational Safety White Paper, jointly published by Peking University and the University of Pennsylvania, states that approximately 26% of U.S. adults and 20.4% of Chinese adults suffer from varying degrees of obstructive sleep apnea.

ResMed (NYSE: RMD), a manufacturer of medical products for respiratory diseases, recently launched the AirSense™ 10 series of sleep breathing therapy devices in the Chinese market, including the AirSense™ 10 Elite Plus fixed pressure single-level ventilator, the AirSense™ 10 Autoset™ Plus fully automated single-level The AirSense™ 10 series includes the AirSense™ 10 Elite Plus set pressure single level ventilator, the AirSense™ 10 Autoset™ Plus fully automatic single level ventilator, and the AirSense™ 10 Autoset™ for Her Plus soothing sleep apnea ventilator with unique algorithms to help improve breathing and sleep for the appropriate population.

New AirSense 10 Series Launched

The AirSense™ 10 series continues ResMed's tradition of providing solutions for sleep and breathing problems in the chronic disease area and is ResMed's latest achievement in caring for patients and healthcare workers in the areas of chronic disease management and improving comfort.

Throughout the development of sleep ventilators, from the initial sizeable respiratory therapy equipment for hospital use only to the later compact and silent automatic ventilators, to the more intelligent sleep breathing products that can detect the time of sleep, ResMed has been leading the change of the whole ventilator industry.

On the other hand, the development process of the entire industry is also the process of patients' awareness of ventilators. Nowadays, patients are more concerned about the effectiveness and comfort of their treatment when purchasing a ventilator.

The AirSense™ 10 series sleep apnea devices use new sleep onset monitoring technology to accurately detect when the user falls asleep and adjust the treatment pressure to the prescribed level. We must ensure a comfortable experience from the moment the user turns on the device and falls asleep.

At the same time, the fully automated pressure regulation algorithm monitors the patient's breathing and, at first, the sign of a slight upper airway collapse. And it can begin to gently increase the pressure until the event clears, ensuring an open upper airway.

In addition, the ResMed AirSense™ 10 Series sleep apnea devices are equipped with an automatic light sensor that adjusts the screen's brightness according to the room light. And it makes it easy for patients to change the device with the lights off while avoiding the stimulation of light that can affect the sleep of patients and their families.

ResMed's global R&D department continues to develop more targeted products for specific patients based on user feedback. The new ResMed AirSense™ 10 series is segmented for different patients.

The AirSense™ 10 Autoset™ For Her Plus ventilator with a soothing mode for minor snoring provides more sensitive treatment for minor upper airway collapse. This minimizes sleep disturbance to ensure quality sleep. Lean R&D technology coupled with product segmentation that matches patient characteristics can better meet patients' needs symptomatically.

ResMed, a leading global developer of medical solutions for respiratory diseases with more than 5,000 patented designs, is listed on the New York Stock Exchange (NYSE) and Australia (ASX) and is focused on treating and responding to sleep-disordered breathing disorders, chronic obstructive pulmonary disease.

Other chronic respiratory diseases. Today, ResMed products are in use in more than 100 countries, providing quality solutions to millions of patients worldwide each year. Since it entered China in 2007, ResMed has provided Chinese patients with a comfortable sleep experience through its superior product performance and comprehensive solutions.

The new ResMed AirSense™ 10 series in China will help more Chinese patients improve their sleep and breathing. Enhance their quality of life, reduce the impact of chronic diseases and help them save on healthcare costs.